Innova Captab Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Innova Captab Ltd filed with BSE on 14 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Innova Captab reported full year FY26 revenue of INR1,630 crores, up 31% year-on-year, with Q4 revenue at INR448 crores, up 42% year-on-year. Growth was driven by both the CDMO business, which grew 24% for the year, and the Branded Generics business, which grew 51%. Management said the Jammu facility completed its first full year of operation and is expected to move towards EBITDA breakeven in the coming quarters.
Numbers mentioned
Revenue: INR1,630 crores (FY26)
p. 3
“On a full year basis, revenue stood at INR1,630 crores, registering a healthy growth of 31% year-on-year, while Q4 revenue come at INR448 crores, delivering a strong growth of 42% compared to the corresponding quarter last year.”
Vinay Lohariwala, page 3 of the filed PDF · View the filing
Q4 Revenue: INR447.8 crores (Q4 FY26)
p. 4
“Consolidated revenue for the quarter came in at INR447.8 crores, with a strong 42% year-on-year growth, mainly driven by strong demand in both our business areas.”
Lokesh Bhasin, page 4 of the filed PDF · View the filing
CDMO business revenue: INR1,133 crores (FY26)
p. 3
“The CDMO business reported revenue of INR1,133 crores, during FY '26, reflecting a year-on-year growth of 24%.”
Vinay Lohariwala, page 3 of the filed PDF · View the filing
Exports contribution: 28% (Q4 FY26)
p. 4
“Exports contributed 28% for quarter 4, reflecting our continued focus and progress in global markets.”
Lokesh Bhasin, page 4 of the filed PDF · View the filing
CDMO business revenue: INR314.8 crores (Q4 FY26)
p. 4
“Our CDMO business revenue came in at INR314.8 crores, up by 41% year-on-year, mainly led by increased product portfolio, adding new customers and deepening our wallet share with”
Lokesh Bhasin, page 4 of the filed PDF · View the filing
Branded Generics business revenue: INR133 crores (Q4 FY26)
p. 5
“existing customers. The Branded Generics business revenue stood at INR133 crores, growth of 46% on a year-on-year basis, showcasing a pure testament to our distribution strategies.”
Lokesh Bhasin, page 5 of the filed PDF · View the filing
EBITDA: INR66.7 crores (Q4 FY26)
p. 5
“EBITDA for the quarter stood at INR66.7 crores with 31% increase and EBITDA margin of 14.9%, mainly due to change in product mix.”
Lokesh Bhasin, page 5 of the filed PDF · View the filing
Profit after tax: INR38.1 crores (Q4 FY26)
p. 5
“Profit after tax for the quarter came in at INR38.1 crores, up 29% on a year-on-year basis.”
Lokesh Bhasin, page 5 of the filed PDF · View the filing
Exports contribution: 31% (FY26)
p. 5
“Exports for the full year contributed 31% to the overall revenue.”
Lokesh Bhasin, page 5 of the filed PDF · View the filing
Branded Generics business revenue: INR497 crores (FY26)
p. 5
“Branded Generics business showed robust growth of 51% and came in at INR497 crores.”
Lokesh Bhasin, page 5 of the filed PDF · View the filing
EBITDA: INR250.3 crores (FY26)
p. 5
“EBITDA for the full year came in at INR250.3 crores as against INR198.2 crores last year.”
Lokesh Bhasin, page 5 of the filed PDF · View the filing
Operating margin: 15.4% (FY26)
p. 5
“Operating margins for FY '26 came in at 15.4%.”
Lokesh Bhasin, page 5 of the filed PDF · View the filing
Profit after tax: INR140.9 crores (FY26)
p. 5
“Profit after tax stood at INR140.9 crores with a growth of 10% on a year-on-year basis.”
Lokesh Bhasin, page 5 of the filed PDF · View the filing
Jammu facility revenue: around INR300 crores (FY26)
p. 8
“So this quarter, so basically, if you talk about full year, Jammu is achieved around INR300 crores.”
Lokesh Bhasin, page 8 of the filed PDF · View the filing
Sharon Bio revenue: around INR240-odd crores (FY26)
p. 11
“This year, their revenue is around INR240-odd crores.”
Lokesh Bhasin, page 11 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Revenue growth — 20% plus
stated as an aspiration by Vinay Lohariwala
p. 4
“we are confident in our ability to deliver 20% plus revenue growth and create long-term value for our stakeholders.”
Vinay Lohariwala, page 4 of the filed PDF · View the filing
EBITDA growth relative to revenue
stated as an aspiration by Vinay Lohariwala
p. 4
“we expect EBITDA growth to outperform revenue growth, as the Jammu plant utilization ramp up further.”
Vinay Lohariwala, page 4 of the filed PDF · View the filing
PAT growth relative to EBITDA growth
stated as an aspiration by Vinay Lohariwala
p. 4
“PAT growth should outpace EBITDA growth added by the fact that the depreciation and financial costs related to the Jammu facility are largely fixed and already reflected in the base.”
Vinay Lohariwala, page 4 of the filed PDF · View the filing
EBITDA margin — FY27
stated as an aspiration by Vinay Lohariwala
p. 7
“Next year, the margin should be better than the current year.”
Vinay Lohariwala, page 7 of the filed PDF · View the filing
Jammu facility EBITDA — EBITDA positive · coming quarter
stated conditionally by Lokesh Bhasin
p. 8
“We are very much positive that in coming quarter, we should be able to achieve EBITDA positive as well as start covering the fixed cost on Jammu part.”
Lokesh Bhasin, page 8 of the filed PDF · View the filing
New Baddi capex — INR150 crores to INR170 crores · FY27 and FY28
stated conditionally by Lokesh Bhasin
p. 10
“the overall capital outlay should be in the range of INR150 crores, INR170 crores.”
Lokesh Bhasin, page 10 of the filed PDF · View the filing
New Baddi block revenue potential — INR450 crores to INR500-odd crores
stated as an aspiration by Lokesh Bhasin
p. 10
“the overall potential of this block at an optimum level should be in the range of INR450 crores to INR500-odd crores revenue.”
Lokesh Bhasin, page 10 of the filed PDF · View the filing
Group volume growth — 20% plus · FY27
stated firmly by Lokesh Bhasin
p. 13
“we are very much confident of maintaining that 20% plus volume growth from FY '26 to FY '27.”
Lokesh Bhasin, page 13 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management confirmed raw material prices had risen due to the conflict but said the cost-plus pricing model with CDMO customers allowed most of the increase to be passed through.
Answered by Lokesh Bhasin
Asked by Anubhav: Whether API prices are spiking due to the Middle East situation and if this can be passed on in CDMO revenue.
p. 6
“So yes, so due to this going on conflict, there is certain uptick in prices of our raw materials and major ingredients.”
Lokesh Bhasin, page 6 of the filed PDF · View the filing
Management said availability was not a concern, only prices had risen due to supply-side disruption rather than a demand shock like during COVID.
Answered by Vinay Lohariwala
Asked by Sudarshan Padmanabhan: Whether there are raw material supply chain issues given global disruptions.
p. 6
“as far as the availability is concerned, there is no such problem, what should I say, so prices are going up.”
Vinay Lohariwala, page 6 of the filed PDF · View the filing
Management said Jammu was near EBITDA breakeven this quarter and expected to turn EBITDA positive in the coming quarter.
Answered by Lokesh Bhasin
Asked by Ankit Shah: What were Jammu's revenues this quarter and has it started contributing positively to EBITDA.
p. 8
“this quarter, we are nearing EBITDA.”
Lokesh Bhasin, page 8 of the filed PDF · View the filing
Management attributed the gross margin change entirely to product mix shifts, not raw material cost increases.
Answered by Lokesh Bhasin
Asked by Ankit Shah: Why gross margins declined year-on-year despite branded business share increasing.
p. 8
“the change in gross margin profile is mainly due to the change in product mix.”
Lokesh Bhasin, page 8 of the filed PDF · View the filing
Management said prices had stabilized before the conflict but increases were visible on a year-to-date basis in April.
Answered by Vinay Lohariwala
Asked by Avneesh Burman: Whether cephalosporin API prices rose meaningfully on a sequential basis.
p. 9
“with the April, if we see on the YTD basis, then we can say, yes, there is an increase in the prices.”
Vinay Lohariwala, page 9 of the filed PDF · View the filing
Management explained the Baddi land is for a general oral tablet, capsule and liquid facility to relieve capacity pressure, as the existing Baddi facility is running at high utilization.
Answered by Vinay Lohariwala
Asked by Rajas Joshi: Reasoning behind the Baddi land purchase and whether a capacity crunch exists.
p. 10
“if you see our Baddi portfolio, we are going on a higher utilization side.”
Vinay Lohariwala, page 10 of the filed PDF · View the filing
Management said Sharon's revenue was around INR240-odd crores and its margin profile is better than the company average given its export regulatory market focus.
Answered by Lokesh Bhasin
Asked by Gourav Bhama: How has Sharon Bio performed this year in terms of revenue and margins.
p. 11
“So their margin profile is better as far as our average EBITDA margin is concerned.”
Lokesh Bhasin, page 11 of the filed PDF · View the filing
Management said the exit run rate was over INR90 crores per quarter and reiterated overall group volume growth guidance rather than a facility-specific figure.
Answered by Lokesh Bhasin
Asked by Viraj Shah: What is the expected Jammu revenue run rate and FY27 guidance.
p. 13
“our exit run rate was INR90 crores plus for this quarter.”
Lokesh Bhasin, page 13 of the filed PDF · View the filing
Risks flagged
Rising raw material and API prices due to the ongoing geopolitical conflict.
p. 6
“there is certain uptick in prices of our raw materials and major ingredients.”
Lokesh Bhasin, page 6 of the filed PDF · View the filing
Supply-side disruption affecting prices, distinct from a demand-side disruption.
p. 7
“there are some disruptions on the supply side.”
Vinay Lohariwala, page 7 of the filed PDF · View the filing
Cephalosporin API price volatility affecting revenue during the year.
p. 8
“there has been impact from Jammu as we have called out earlier. That was the major impact, which has impacted our revenue during this year.”
Lokesh Bhasin, page 8 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.